Can Nestlé’s new snack strategy rival the soaring demand for weight-loss drugs?

Nestlé’s launch of Boost Pre-Meal Hunger Support signals a strategic shift in response to changing market dynamics. The booming weight-loss industry – projected to reach $150bn annually within the next decade – is reshaping the food sector. GLP-1 medications like Wegovy and Zepbound have disrupted traditional eating habits, with retailers such as Walmart noting reduced food sales among users, pushing companies to innovate swiftly to stay competitive. Created as a pre-meal appetite suppressant, the Boost protein shot utilises whey protein micro-gels to trigger the natural release of GLP-1, the appetite-regulating hormone. Offering a milder and more accessible option than pharmaceutical alternatives – designed to complement rather than replace weight-loss meds – each shot is fat free and contains 1g of sugar to come in at 45 calories. It also punches in with 10g of whey protein, which Stefan Palzer, Nestlé’s chief technology officer, said has a significant impact on satiety. “You get an increase in natural GLP-1, which helps in controlling the feeling of hunger,” said Palzer. According to Nestlé, its patented whey protein micro-gel technology is designed to deliver a rapid amino acid spike that helps control hunger while slowing digestion. This dual action allows the micro-gels to interact longer with intestinal receptors, enhancing the release of the appetite-regulating hormone GLP-1. A randomised study involving 26 people with type-2 diabetes in 2021 demonstrated its effectiveness. Participants alternated between consuming a low-dose whey protein micro-gel and a placebo before meals. The results showed a 22% reduction in post-meal glucose levels for those who consumed the whey protein compared to the placebo group, alongside a noticeable increase in GLP-1 levels. However, Prof Lora Heisler, director of Research at the Rowett Institute of Nutrition and Health, University of Aberdeen, has expressed reservations about the long-term efficacy for people trying to lose weight. “I believe this protein shot can help release a bit more GLP-1, but you can also possibly have a similar sort of release with a glass of milk,” she told the media. One notable advantage is the affordability of the Nestlé’s Boost Pre-Meal Hunger Support. Priced at $10.99 for a four-pack, each serving costs about $2.75 – significantly cheaper than prescription GLP-1 agonist Wegovy, which ranges from $1,300 to $1,600 per month in the US without insurance. This sharp price contrast positions Nestlé’s pre-dinner ‘snack’ as an accessible, over-the-counter option for those looking to curb hunger without the steep expense or medical prescriptions associated with pharmaceutical alternatives. This isn’t the first time the Kit Kat maker has explored the weight-loss market. Earlier in 2024, the company introduced protein-enriched pastas and frozen pizzas (at the very afford $5 price mark), leveraging its patented whey protein micro-gels to cater to individuals using weight-loss medications. The rise of weight-loss drugs poses both challenges and opportunities for the food industry. As consumer calorie intake decreases in certain demographics, companies must shift focus from volume-based sales to value-driven offerings. Nestlé’s protein shot exemplifies this shift, as it emphasises functionality and purpose over traditional indulgence. This pivot represents a reimagining of value propositions, with brands competing on quality, innovation and alignment with health trends. Another implication is the increasing convergence of the food and health sectors. Nestlé’s patented microgel technology illustrates how food manufacturers are drawing inspiration from pharmaceuticals to create products that address specific physiological needs. Such innovations could pave the way for cross-sector collaborations, where the biotech and food industries work together to develop advanced functional foods. However, the road ahead is not without hurdles. Establishing consumer trust in the efficacy of these products will be critical, especially as experts voice doubts about their benefits compared to simpler dietary adjustments. Additionally, competition from both established brands and smaller, nimble players in the functional food space will intensify as the market grows. One thing is certain: Nestlé’s move into the weight-loss market sends a clear message – adaptation is no longer optional. The era of one-size-fits-all food products is giving way to a growing demand for personalised, science-driven solutions. To stay competitive, companies must ramp up their R&D efforts or face the risk of falling behind.

Can Nestlé’s new snack strategy rival the soaring demand for weight-loss drugs?

The maker of Kit Kat, Haagen-Dazs and Cheerios is once again addressing the growing popularity of weight-loss drugs with a protein shot designed to curb appetite. But can it hold its own in the booming market for targeted health-focused solutions?

Related Topics